Cannabinoid hyperemesis syndrome
|Cannabinoid hyperemesis syndrome|
|Classification and external resources|
Cannabinoid hyperemesis syndrome is characterized by recurrent nausea, vomiting and crampy abdominal pain. These symptoms have been reported to be improved temporarily by taking a hot shower or bath or more fully by stopping the use of cannabis.
The syndrome was described by Allen and colleagues (2004), and Sontineni and colleagues (2009) who offer simplified clinical diagnostic criteria. A subsequent, larger study reported a case series of 98 subjects with cannabinoid hyperemesis syndrome, confirming the earlier reported findings.
Signs and symptoms
|Essential||Cannabis use for years|
|Major||Severe nausea and vomiting
Vomiting that recurs in a cyclic pattern over months
Resolution of symptoms after stopping cannabis use.
|Supportive||Compulsive hot baths with symptom relief
Colicky abdominal pain
No evidence of gall bladder or pancreatic inflammation
|Essential||Long-term cannabis use|
|Major||Severe cyclic nausea and vomiting
Resolution with cannabis cessation
Relief of symptoms with hot showers or baths
Abdominal pain, epigastric or periumbilical
Weekly use of marijuana.
|Supportive||Age less than 50 y
Weight loss of >5 kg
Morning predominance of symptoms
Normal bowel habits
Negative laboratory, radiographic, and endoscopic test results
Sontineni and colleagues in 2009 discussed the cannabinoid hyperemesis syndrome to offer guidelines for the clinical diagnosis.
Various pathogenic mechanistic theories attempting to explain symptoms have been put forward. These theories follow two themes: 1) dose dependent buildup of cannabinoids and related effects of cannabinoid toxicity, and 2) the functionality of cannabinoid receptors in the brain and particularly in the hypothalamus (which regulates body temperature and the digestive system). But the mechanisms by which cannabis causes or controls nausea and the adverse consequences of long-term cannabis toxicity remain unknown and organic disease should not be ruled out as a possible cause.
The neurobiology of the compound has led to the discovery of an endogenous cannabinoid system. The therapeutic potential of cannabinoids has been recognized and these compounds are utilized as antiemetics. Several studies have demonstrated the therapeutic effects of cannabinoids for nausea and vomiting in the advanced stages of illnesses such as cancer and AIDS.
The number of people affected is unclear as of 2015.
Many traditional medications for nausea and vomiting are ineffective. However, treatment with lorazepam or haloperidol has provided relief for some people. Assessing for dehydration due to vomiting and hot showers is important as it can lead to cannabinoid hyperemesis acute renal failure (CHARF), and this is easily treated with IV fluids. Treatment is otherwise supportive and focuses on stopping cannabis use.
Acute episodes of cannabinoid hyperemesis typically last for 24–48 hours and the problem often resolves with long term stopping of cannabis use. Improvement can take one to three months to occur.
Relapses are common, and this is thought to be possibly secondary to a lack of education as many people use or increase their use of cannabis due to their symptoms of nausea and vomiting.
- Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA (2016). "Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review". J Med Toxicol. doi:10.1007/s13181-016-0595-z. PMID 28000146.
- Allen, J H; De Moore, GM; Heddle, R; Twartz, JC (2004). "Cannabinoid hyperemesis: Cyclical hyperemesis in association with chronic cannabis abuse". Gut. 53 (11): 1566–70. doi:10.1136/gut.2003.036350. PMC . PMID 15479672.
- Sontineni, Siva-P; Chaudhary, S; Sontineni, V; Lanspa, SJ (2009). "Cannabinoid hyperemesis syndrome: Clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse". World Journal of Gastroenterology. 15 (10): 1264–6. doi:10.3748/wjg.15.1264. PMC . PMID 19291829.
- Simonetto, Douglas A.; Oxentenko, Amy S.; Herman, Margot L.; Szostek, Jason H. (2012). "Cannabinoid Hyperemesis: A Case Series of 98 Patients". Mayo Clinic Proceedings. 87 (2): 114–9. doi:10.1016/j.mayocp.2011.10.005. PMC . PMID 22305024.
- Habboushe J, Sedor J (June 2014). "Cannabinoid hyperemesis acute renal failure: a common sequela of cannabinoid hyperemesis syndrome". Am J Emerg Med. 32 (6): 690.e1–2. doi:10.1016/j.ajem.2013.12.013. PMID 24418446.
- "NCPIC.Cannabinoid hyperemesis syndrome". Ncpic.org.au. Retrieved 2016-07-23.
- Davis, Mellar; Maida, Vincent; Daeninck, Paul; Pergolizzi, Joseph (2006). "The emerging role of cannabinoid neuromodulators in symptom management". Supportive Care in Cancer. 15 (1): 63–71. doi:10.1007/s00520-006-0180-0. PMID 17139494.
- World health Organization, Cannabis - epidemiology.
- Galli, JA; Sawaya, RA; Friedenberg, FK (December 2011). "Cannabinoid hyperemesis syndrome". Current drug abuse reviews. 4 (4): 241–9. doi:10.2174/1874473711104040241. PMC . PMID 22150623.
- Lu, ML; Agito, MD (July 2015). "Cannabinoid hyperemesis syndrome: Marijuana is both antiemetic and proemetic". Cleveland Clinic journal of medicine. 82 (7): 429–34. doi:10.3949/ccjm.82a.14023. PMID 26185942.
- King, Chelsey; Holmes, Andrew (2015-03-17). "Cannabinoid hyperemesis syndrome". Canadian Medical Association Journal. 187 (5): 355. doi:10.1503/cmaj.140154. ISSN 1488-2329. PMC . PMID 25183721.
- Wallace, Erik A.; Andrews, Sarah E.; Garmany, Chad L.; Jelley, Martina J. (2011-09-01). "Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm". Southern Medical Journal. 104 (9): 659–664. doi:10.1097/SMJ.0b013e3182297d57. ISSN 1541-8243. PMID 21886087.
- Sun, S; Zimmermann, AE (September 2013). "Cannabinoid hyperemesis syndrome". Hospital pharmacy. 48 (8): 650–5. doi:10.1310/hpj4808-650. PMC . PMID 24421535.